Previous Meeting: 10th Course in 2012

Program 2012



Medicinal Chemistry: The Only constant is Change

Prof. Beat Ernst, University of Basel

Nuclear Hormone Receptors as Drug Targets

Prof. Pedro Hermkens, University of Nijmegen

Rules and Filters and their Impact on Success in Chemical Biology and Drug Discovery

Dr. C. Lipinski, Melior Discovery

Developing a Lead

Dr. Andrew Mortlock, AstraZeneca

Fragment-Based Drug Discovery

Prof. Beat Ernst, University of Basel

Privileged Structures

Dr. Gerhard Müller, Mercachem

Early ADMET: Compound Profiling and Optimization in Drug Discovery

Dr. Manfred Kansy, Hoffmann-La Roche

Experimental ADME: Major DMPK Properties to Assess During Lead Optimization

Dr. Christoph Funk, F. Hoffmann-La Roche

Drug Metabolism

Prof. Hugo Kubinyi, University of Heidelberg


Dr. Robert A. Copeland, Epiyzme

Natural Product-Based Drugs

Prof. Karl-Heinz Altmann, ETHZ

Proteases as Drug Targets

Dr. Richard Sedrani, Novartis

Structure-Based Design on G Protein-Coupled Receptors

Dr. Jonathan Mason, Heptares

Kinetics and Thermodynamics of Binding

Dr. David Swinney, Institute for Rare and Neglected Diseases Drug Discovery

Structure-Based Drug Design: Applications and Limitations

Dr. Alexander Alex, Alexander Alex Consulting

GPCRs as Drug Targets

Dr. Rogier Buijsman, NTRC

Prodrugs and Soft Drugs

Prof. Hugo Kubinyi, University of Heidelberg

Biochemical Profiling in Early Drug Discovery

Dr. Doris Hafenbradl, Biofocus-Galapagos


Dr. Nicholas Meanwell, Bristol-Myers Squibb

Protein–Protein Interactions

Dr. Daniel Obrecht, Polyphor

Kinases as Drug Targets

Dr. Gerhard Müller, Mercachem

Personalized Medicine

Dr. Hartmuth C. Kolb, Siemens

In vivo Efficacy Models

Dr. Cathleen Lutz, Jackson Laboratories




Physicochemical Parameters Relevant for Drug Absorption

Robert Taylor and Darren Matthews, Sinus Analytical

Fragment-Based Lead Generation

Dr. Mark Whittaker and Dr. Michael P. Mazanetz, Evotec

Developing a Lead

Dr. Andrew Mortlock, AstraZeneca

Structure-Based Lead Optimization

Dr. Tien Luu, Accelrys

IP in Drug Discovery

Dr. Frank Schager, Actelion

The NMR Toolbox for Medicinal Chemists

Dr. Christoph Rademacher, Max Planck Institute of Colloids and Interfaces


Dr. Ruben Leenders and Dr. Johan Veerman, Mercachem


Case Histories

Target Structure and Physical Property-Based Approaches Applied for Cancer Drug Discovery

Dr. Alan D. Brown, Pfizer

FXa Inhibitors as Anticoagulant Drugs

Dr. Susanne Röhrig, Bayer

A New Treatment Option for Multidrug-Resistant Tubercolosis: Discovery of Bedaquiline (TMC207)

Dr. Kristof van Emelen, Janssen